Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 13, 2020 - Issue 7
Submit an article Journal homepage
12,983
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review

F. H. van BruggenUniversity of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine, Groningen, The NetherlandsView further author information
,
G. B. J. NijhuisUniversity of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine, Groningen, The NetherlandsView further author information
,
S. U. ZuidemaUniversity of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine, Groningen, The NetherlandsView further author information
&
Hendrika LuijendijkUniversity of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine, Groningen, The NetherlandsCorrespondence[email protected]
View further author information
Pages 787-796 | Published online: 13 Jul 2020

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

F. H van Bruggen, G. B. J. Nijhuis, S. U. Zuidema & H. J. Luijendijk. (2021) Response to letter to the editor re: ‘serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review’. Expert Review of Clinical Pharmacology 14:2, pages 283-284.
Read now
Marc S. Sabatine, Robert P. Giugliano & Gregory G. Schwartz. (2021) Letter to the editor re: ‘serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review’. Expert Review of Clinical Pharmacology 14:2, pages 281-282.
Read now

Articles from other publishers (14)

Jitendra Gupta & Reena Gupta. (2023) PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives. Current Molecular Pharmacology 16:8.
Crossref
Hongzhen Chen & Xiaomin Chen. (2023) PCSK9 inhibitors for acute coronary syndrome: the era of early implementation. Frontiers in Cardiovascular Medicine 10.
Crossref
Gavin M. Traber & Ai-Ming Yu. (2023) RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. Journal of Pharmacology and Experimental Therapeutics 384:1, pages 133-154.
Crossref
Xin Zhou, Ziping Li, Hangkuan Liu, Yongle Li, Dong Zhao & Qing Yang. (2023) Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering: current evidence, clinical implications, and future perspectives. Chinese Medical Journal 136:6, pages 645-652.
Crossref
Jimin Hong, Minkyung Bae & Bohkyung Kim. (2022) Effects of Bilberry Extract on Hepatic Cholesterol Metabolism in HepG2 Cells. Applied Sciences 13:1, pages 516.
Crossref
Juan Erviti, James Wright, Ken Bassett, Mohamed Ben-Eltriki, Ciprian Jauca, Luis Carlos Saiz, Leire Leache, Marta Gutiérrez-Valencia & Thomas L Perry. (2022) Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data. BMJ Open 12:12, pages e060172.
Crossref
Volker J. J. Schettler, Christian Peter, Thomas Zimmermann, Ulrich Julius, Eberhard Roeseler, Georg Schlieper, Franz Heigl, Peter Grützmacher, Iris Löhlein, Reinhard Klingel, Bernd Hohenstein, Wolfgang Ramlow & Anja Vogt. (2022) The German Lipoprotein Apheresis Registry—Summary of the ninth annual report. Therapeutic Apheresis and Dialysis 26:S1, pages 81-88.
Crossref
Silvina Ilut, Bianca O. Pirlog, Radu Pirlog, Andreea Nutu, Vitalie Vacaras & Sebastian M. Armean. (2022) Recent Advances on the Roles of PCSK-9 Inhibitors in the Management of Acute Ischemic Stroke Patients. International Journal of Molecular Sciences 23:18, pages 10221.
Crossref
Amir Abbas Momtazi-Borojeni, Matteo Pirro, Suowen Xu & Amirhossein Sahebkar. (2022) PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective. Current Medicinal Chemistry 29:6, pages 980-999.
Crossref
Folkert H. van Bruggen & Hendrika J. Luijendijk. (2021) Evolocumab’s Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER. American Journal of Cardiovascular Drugs 22:1, pages 5-8.
Crossref
Gaetano Santulli, Stanislovas S Jankauskas & Jessica Gambardella. (2021) Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk. European Heart Journal - Cardiovascular Pharmacotherapy 7:3, pages e11-e12.
Crossref
Raimondo FEMINÒ, Giovanni FEMINÒ, Attilio CAVEZZI & Emidio TROIANI. (2021) PCSK9 inhibition, LDL and lipopolysaccharides: a complex and "dangerous" relationship. International Angiology 40:3.
Crossref
Robert A. Hegele. (2021) Editorial comment: when Mendelian randomization goes astray. Current Opinion in Lipidology 32:2, pages 79-80.
Crossref
Mateusz Maligłówka, Łukasz Bułdak, Bogusław Okopień & Aleksandra Bołdys. (2021) Skutki hamowania funkcji PCSK9 w obrębie wybranych tkanek * . Postępy Higieny i Medycyny Doświadczalnej 75:1, pages 385-397.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.